- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01951573
Evaluation of a New Daily Disposable Multifocal Contact Lens Design
November 24, 2014 updated by: Alcon Research
Delefilcon A Multifocal Plus Power Lens Design Evaluation
The purpose of this study is to demonstrate non-inferiority of a new daily disposable multifocal contact lens in plus powers against the commercially available AIR OPTIX® AQUA MULTIFOCAL (AOAMF) lens in high contrast/high illumination (HC/HI) near visual acuity (VA).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with normal eyes who are not using any ocular medication.
- Must sign the Informed Consent document.
- Habitual lens power within the range available for the study lenses (+1.00 to +3.50 diopters(D)).
- Manifest cylinder less than or equal to 0.75D.
- Best corrected distance VA greater than or equal to 20/25 in each eye.
- Existing soft contact lens (CL) wearers who wear contact lenses in both eyes at least 5 days per week.
- Presbyopic with a spectacle addition (ADD) >0.50D and <2.75D.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Any ocular disease, inflammation, or abnormality that contraindicates CL wear.
- Any use of systemic or ocular medications for which CL wear could be contraindicated.
- History of herpetic keratitis.
- History of refractive surgery or irregular cornea.
- A clinically significant dry eye that precludes CL wear.
- Participation of the subject in a clinical study (including CL or CL care product) within the previous 30 days.
- Monocular (only 1 eye with functional vision).
- History of intolerance or hypersensitivity to any component of the test articles.
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Delefilcon A MF, then AOAMF
Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses.
Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
|
Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
Other Names:
|
|
OTHER: AOAMF, then Delefilcon A MF
Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses.
Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
|
Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
High Contrast/High Illumination (HC/HI) Binocular Visual Acuity (VA) at Near
Time Frame: Dispense (Day 1), Hour 9
|
Near VA was assessed binocularly (both eyes together) at 40 centimeters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution).
A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.
|
Dispense (Day 1), Hour 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HC/HI Binocular VA at Distance
Time Frame: Dispense (Day 1), Hour 9
|
Distance VA was assessed binocularly (both eyes together) at 6 meters, with over-refraction (OR), if necessary, and measured in logMAR units (logarithm of the minimum angle of resolution).
A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity, with a negative value denoting better than 20/20 visual acuity.
|
Dispense (Day 1), Hour 9
|
|
Over-refraction (OR) Monocular at Distance
Time Frame: Dispense (Day 1), Hour 9
|
OR (the amount of additional correction needed to improve VA) at distance (equivalent to 6 meters) was assessed monocularly (for each eye separately) in diopters (D).
Both eyes contributed to the mean.
|
Dispense (Day 1), Hour 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Joachim Nick, Dipl. Ing., CIBA VISION GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (ACTUAL)
November 1, 2013
Study Completion (ACTUAL)
November 1, 2013
Study Registration Dates
First Submitted
September 24, 2013
First Submitted That Met QC Criteria
September 24, 2013
First Posted (ESTIMATE)
September 26, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
December 2, 2014
Last Update Submitted That Met QC Criteria
November 24, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-13-011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractive Error
-
Alcon ResearchCompletedRefractive Error - Myopia Severe | Refractive Error - Myopia SimpleUnited States, Ireland, Singapore
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vision Service PlanCompletedRefractive Error - Myopia BilateralUnited States
-
Vision Service PlanCompletedRefractive Error - Myopia BilateralUnited States
-
Wang HongxiaTianjin Eye HospitalCompletedRefractive Error - Myopia AxialChina
-
KK Women's and Children's HospitalWithdrawnRefractive Error - Myopia
-
Tianjin Eye HospitalRecruitingMyopia; Refractive ErrorChina
-
Myoptechs, IncUniversity of Waterloo School of Optometry and Vision ScienceNot yet recruitingMyopia: Refractive Error
-
Perfect Lens, LLCCompletedRefractive Error CorrectionPanama
-
Essilor InternationalRecruitingRefractive Error | AmetropiaUnited States
Clinical Trials on Delefilcon A multifocal contact lenses
-
Alcon, a Novartis CompanyCompletedRefractive ErrorUnited States
-
Alcon, a Novartis CompanyCompletedRefractive Error
-
Alcon ResearchTerminatedPresbyopia | Astigmatism | Myopia | HyperopiaUnited States
-
Alcon ResearchCompletedRefractive Error | PresbyopiaJapan
-
Alcon ResearchCompletedRefractive Errors | PresbyopiaUnited States, Canada, United Kingdom
-
Alcon ResearchCompletedRefractive Errors | Myopia | HyperopiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
Alcon ResearchCompletedRefractive ErrorsUnited States
-
Alcon ResearchCompleted